ArticleOpen forum infectious diseases2025
Analysis of Clinical Subphenotypes in Methicillin-Resistant
Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Rationalizing Heterogeneity in Staphylococcus aureus Bacteremia: Current Progress and Future Goals.The Journal of infectious diseases · 2026Review
- Impact of Methicillin Resistance on Outcomes ofOpen forum infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We aimed to identify and evaluate clinical subphenotypes in a cohort of patients with methicillin-resistant Methods: This post hoc analysis of the MRSA-GEIRAS-SEIMC study was conducted across 15 Spanish hospitals. MRSAB in adult patients from 2019 to 2022 were included. Clinical subphenotypes were identified using a combination of principal component analysis and latent class analysis based on age, sex, comorbidities, SOFA score, creatinine levels, metastatic foci, source, and acquisition. The 90-day mortality associated with each subphenotype was estimated using the Kaplan-Meier method. Cox regression was performed to assess the risk of death. Results: A total of 419 MRSAB were included. Four distinct subphenotypes were identified: S1 was associated with younger age, community acquisition, and unknown or skin and soft-tissue infection source; S2 was associated with older age, female sex, high burden of comorbidities, and healthcare-related acquisition; S3 was linked to a catheter source and nosocomial acquisition; and S4 was predominantly associated with the presence of heart valve prostheses, and metastatic foci. Significant differences in all-cause 90-day mortality were observed across subphenotypes: 20.0% in S1, 47.4% in S2, 26.2% in S3, and 35.1% in S4 ( Conclusions: We identified 4 distinct clinical subphenotypes of MRSAB associated with prognostic outcomes. Further investigation is needed to implement them into clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.